Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Zai Lab Ltd (ZLAB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZLAB at 36.1/100 on a 32-signal composite quality model, placing it at rank #2,280 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Zai Lab Ltd reports quarterly revenue of $106.3M, net income of $-50.8M, free cash flow of $-64.7M. Top institutional holders of ZLAB by reported 13-F value include RTW INVESTMENTS, TCG Crossover Management, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. ZLAB trades on the Nasdaq exchange and files with the SEC under CIK 1704292. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZLAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zai Lab Ltd directly from SEC EDGAR.
AI Quality Score
36.1/100
AI Rank
#2,280
Revenue
$106.3M
Net Income
$-50.8M
Free Cash Flow
$-64.7M
| Period | Form | Revenue | Net income | Operating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $460.2M | $-175.5M | -49.9% |
| FY 2024 | 10-K | $399.0M | $-257.1M | -70.7% |
| FY 2023 | 10-K | $266.7M | $-334.6M | -137.4% |
| FY 2022 | 10-K | $215.0M | $-443.3M | -188.0% |
| FY 2021 | 10-K | $144.3M | $-704.5M | — |
| FY 2020 | 10-K | $49.0M | $-268.9M | — |
| Institution | Shares | Value | Reported |
|---|---|---|---|
| RTW INVESTMENTS | 6,574,032 | $124.9M | 2026-06-30 |
| TCG Crossover Management | 6,137,627 | $116.6M | 2026-06-30 |
| RA CAPITAL MANAGEMENT, L.P. | 5,743,533 | $109.1M | 2026-06-30 |
| ADAR1 Capital Management | 3,369,034 | $64.0M | 2026-06-30 |
| FMR | 2,815,214 | $53.5M | 2026-06-30 |
| GOLDMAN SACHS GROUP | 2,315,480 | $44.0M | 2026-06-30 |
| Woodline Partners | 2,207,293 | $41.9M | 2026-06-30 |
| Frazier Life Sciences Management, L.P. | 1,902,320 | $36.1M | 2026-06-30 |
| BAMCO | 1,623,694 | $30.9M | 2026-06-30 |
| TWO SIGMA INVESTMENTS | 1,299,394 | $24.7M | 2026-06-30 |
13F Pro Quality Score
Rank #2,280 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.